

Collaborative Sepsis Care at Kaiser Permanente

Vincent Liu, MD MS | Research Scientist, KP Division of Research Carmen Adams DNSc RNC | KFH Strategic Leader, Quality John Morehouse, MD | TPMG Director, Hospital Quality



Agenda

Sepsis care: the KP Northern California experience

Building a learning sepsis system at KPNC

Fluid management in sepsis



Kaiser Permanente Northern California A highly integrated healthcare delivery system



By the numbers:

- 4.1 million patients
- 9,000 physicians
- 16,000 nurses
- 21 hospitals




Sepsis: a matter of public health Common, costly, and deadly

- Affects >1.5m Americans and ~30m people worldwide annually;
- Associated with US healthcare costs of \$20 billion each year;
- Is a factor in at least 1 in every 3 US hospital deaths;
- Results in long-term functional and cognitive decline;
- Is one of the most common reasons for rehospitalization;
- Is poorly recognized and understood by the public.

Hershey/Kahn (NEJM 2017); Liu et al (JAMA 2013); Iwashyna et al (JAMA 2010); Mayr et al (JAMA 2017)




Sepsis: a matter of local health A key driver of inpatient outcomes



Sepsis Timeline @ KPNC


Liu/Morehouse et al (JHM 2016)

Sepsis: coordinated implementation Four key elements






Sepsis: coordinated implementation Leadership Alignment






Sepsis: coordinated implementation Standardization



KAISER PERMANENTE

Sepsis: coordinated implementation Standardization



Playbooks to Expedite Spread

- ✓ Aim
- ✓ Standardized Processes
- ✓ Compelling Story, presentations
- ✓ Implementation Tools
- Assembling your team optimal membership
- ✓ Checklists, sample agendas
- ✓ Training materials for MDs and staff
- ✓ Implementation timelines and measures
- Implementation, process and outcome measurement strategy



Sepsis: coordinated implementation Standardization




Hardwire Orders in the EMR

- Standardize order sets in EMR with antibiotics guide
- Standardize hemodynamic flowsheets with "Time Zero"
- Best practice alert to prompt lactate order with blood culture
- Automatic order of serial lactate in all admission order sets when lactate elevated



Sepsis: coordinated implementation Project Management



Managers and champions are not project managers

Regional project managers /mentors

- Project manage at regional level
- Mentor Improvement Advisors at the Medical Center
- Run collaborative & Conduct site visits
- Monthly Newsletter & Website

Medical Center Improvement Advisors

- Run tests of change
- Oversee local project management
- Support local champions
- Regional IA meetings
- Provide local-regional feedback



Sepsis: coordinated implementation Project Management



Collaboration: learning from those that leap ahead!

- Sepsis alerts
- Intermediate Critical Lactates
- Co-locating blood culture and lactate tubes
- IL and High Risk Bundles on CQC
- Handoff tools



Sepsis: coordinated implementation Project Management


Quality of Team Function

- Participation in sepsis multidisciplinary team meetings
- Discuss the status of the unit (huddles; check-ins)
- Sepsis team meeting minutes (discussion of barriers)
- Review of performance data

Partnering with frontline staff

- Can staff verbalize sepsis screening criteria?
- Do they exhibit awareness of bundle elements and are they comfortable advocating for this treatment?
- Are staff knowledgeable about performance?
- Do they feel valued?


Sepsis: coordinated implementation Data: to quantify changes in sepsis recognition





Sepsis: coordinated implementation


Data: to assess changes in use of lactate (prognostic marker)





Sepsis: coordinated implementation


Data: to evaluate changes in sepsis risk-adjusted mortality



Sepsis: coordinated implementation


Data: to quantify changes in hospital-wide risk-adjusted mortality

Hospital Standardized Mortality Ratio (HSMR) Rolling 12 months





Sepsis: driving new discovery Moving beyond EGDT



Sepsis Timeline @ KPNC

Liu/Morehouse et al (JHM 2016)

Sepsis: intermediate lactate patients Intermediate risk patients and hospital mortality

	N	EGDT- eligible		
	Normal	Intermediate	None	
Mortality rate, %	5.3%	8.9%	10.6%	23.3%
% of all sepsis deaths	26.3%	29.6%	11.6%	22.6%

Liu et al (JAMA 2014)



Sepsis: intermediate lactate patients


Leveraging data from a large population of KPNC sepsis patients


	Study design	Sample size	
Shapiro et al	Prospective	267	
Howell et al	Prospective	246	
Trzeciak et al	Prospective	238	
Mikkelsen et al	Retrospective	415	
Glickman et al	Prospective	138	
Song et al	Retrospective	474	
Arnold et al	Prospective	94	
Liu et al	Retrospective	9,190	

Puskarich et al (J Crit Care 2014)



Sepsis: intermediate lactate patients Leveraging data from a large population of KPNC sepsis patients






Liu/Morehouse et al (Annals ATS 2013)

KAISER PERMANENTE®

Sepsis: intermediate lactate patients Leveraging data from a large population of KPNC sepsis patients






Liu/Morehouse et al (Annals ATS 2013)




Sepsis: intermediate lactate patients Instituting a bundle based on best evidence and sepsis principles





Sepsis: intermediate lactate patients Bundle compliance before and after implementation





Sepsis: intermediate lactate patients Outcomes stratified by history of CHF or CKD

Mortality before and after IL Bundle Implementation


	n	2011	2012	2013	P-value
			Mortality (%)	IL Bundle I	mplementation
All patients (hospital)	18,122	8.8	9.3	7.9	0.02
All patients (30-day)		13.7	14.1	12.6	0.03
CHF/CKD (hospital)	8,322	10.7	12.5	8.7	<0.01
CHF/CKD (30-day)		16.8	18.3	14.5	<0.01
No CHF/CKD (hospital)	9,800	7.4	6.5	7.2	0.40
No CHF/CKD (30-day)		11.3	10.5	10.8	0.60

Liu et al (AJRCCM 2015)

25 June 2, 2017 © 2011 Kaiser Foundation Health Plan, Inc. For internal use only.

KAISER PERMANENTE®


Sepsis: intermediate lactate patients Outcomes stratified by history of CHF or CKD



Liu et al (AJRCCM 2015)

KAISER PERMANENTE®

Sepsis: driving new discovery Moving beyond EGDT



Sepsis Timeline @ KPNC


Liu/Morehouse et al (JHM 2016)

Sepsis: where are we today? How do we best treat sepsis patients....





Sepsis: where are we today? Trends in sepsis mortality over 2 decades



Stevenson et al (CCM 2014)

29 June 2, 2017 © 2011 Kaiser Foundation Health Plan, Inc. For internal use only.

KAISER PERMANENTE®

Sepsis: where are we today? Principles for best sepsis care

- Educate your hospital staff about the massive impact that sepsis has on morbidity, mortality, cost, and utilization
- Develop a multidisciplinary team to deliver standardized, coordinated, and rapid sepsis care
- Aim to accelerate the identification of sepsis patients, particularly those at high risk for adverse outcomes
- ✓ Focus on source control through early antibiotics
- Build a data infrastructure that allows you to assess how sepsis program investments impact outcomes
- Fluids are frequently needed for sepsis patients, but recognize that they can have side effects
- ✓ Use dynamic clinical judgment, with ongoing patient reassessment



Sepsis: fluid management

Schematic of physiologic changes after fluid resuscitation




Fig 1 Superimposition of the Frank-Starling and Marik-Phillips curves demonstrating the effects of increasing preload on stroke volume and lung water in a patient who is pre-load responsive (A) and non-responsive (B). With sepsis the EVLW curve is shifted to the left.⁵¹ EVLW=extra-vascular lung water; CO=cardiac output; SV=stroke volume. MCFP=mean circulating filling pressure. Reproduced with permission from the British Journal Anaesthesia; 2014;12:620–622.

Marik and Bellomo (BJA 2015)





Sepsis: fluid management Changes in 72h fluid totals over time





Fig 2 Fluid administered between enrolment and 72 h and 90-day mortality in the control arm of the Early Goal Directed Therapy (EGDT) Studies performed between 2001 and 2015. APACHE II=APACHE II Severity of illness scoring system (0–71).

Marik and Bellomo (BJA 2015)



Sepsis: fluid management IV fluid type




Frost (BMJ 2015)

IV Fluid Type

- No role for hydroethyl starch which was associated with increased mortality
- RCT data finds no definite benefit from albumin versus crystalloid
- However, there is evidence favoring improved mortality with albumin in certain subgroups – so, additional study needed
- There is evidence suggesting mortality benefit from balanced crystalloids; additional study is needed
- No clear reduction in renal replacement therapy

Kaiser Permanente®

Sepsis: fluid management IV fluid timing



Seymour et al (NEJM 2017)

KAISER PERMANENTE®

Sepsis: fluid management Frequent reassessment after IV fluids

Macrocirculatory

Central Venous Pressure: - useless to assess volemia

Arterial Blood Pressure (ABP): - low sensitivity/specificity to detect tissue

- good to predict mortality

Cardiac Output (CO):

- it is only a number

extreme values

of calculation errors.

35 June 2, 2017

- does not tell whether CO meets

inotrope overuse and monitor cosmetics

 $DO_2 = CO * (Hb * 1.36 * S_aO_2 + 0.0031 * P_aO_2)$

Dunser et al (Crit Care 2013)

same as for cardiac output with additional risk

- correlates with tissue perfusion only at

Oxygen Transport Capacity (DO₂):

systemic oxygen demand

- targeting CO carries risk of

targeting ABP carries high risk of vasopressor overuse and monitor cosmetics useful to avoid ABP drops below lower limits of coronary/cerebral autoregulation

hypoperfusion

fluid loading

useful to monitor the cardiac response to

(14)

versus

Tissue Perfusion-Based

Resuscitation Endpoints

Central/Mixed Venous Oxygen Saturation: - indicates whether O₂ delivery meets demands - high values indicate shunting or luxurious blood flow (rarely reduced O₂ consumption

 measure continuously!
prefer mixed venous measurements!
false high measurements in case of severe peripheral vasoconstriction and/or sepsis
good to predict mortality at low and high values

Arterial Lactate: - marker of tissue hypoperfusion (with limitations) and disease severity - good to predict mortality even at moderately elevated levels

·lactate clearance valuable to guide resuscitation other causes than tissue hypoperfusion can increase lactate levels (e.g. B₂-stimulation) currently only intermittent lactate

measurements available



Capiliary Refill Time/Peripheral Perfusion: - indicator of adequacy of systemic blood flow - continuous and quantitative measurement using StO₂ or the peripheral perfusion index - does not exclude visceral organ hypoperfusion due to excessive vasodilation (rare) - unreliable in severe peripheral artery disease - delayed response to treatment (15-60')

Urine Output: - good marker of renal/visceral organ

 good market of renaryscena organ perfusion - delayed response to treatment (15-60') - unreliable in established kidney injury - titration of fluids to urine ouput alone may result in fluid overload - never treat shock-related oliguria with diuretics1

- minute-by-minute measurement of urine flow technically possible

Skin Mottling:

© 2011 Kaiser Foundation Health Plan, Inc. For internal use only.

skin over the knee caps mottles first! indicator of inadequate systemic blood flow never increase vasopressors in case of skin mottling! Mortality will be nearly 100%!










Sepsis: where are we today? Principles for best sepsis care

- Educate your hospital staff about the massive impact that sepsis has on morbidity, mortality, cost, and utilization
- Develop a multidisciplinary team to deliver standardized, coordinated, and rapid sepsis care
- Aim to accelerate the identification of sepsis patients, particularly those at high risk for adverse outcomes
- ✓ Focus on source control through early antibiotics
- Build a data infrastructure that allows you to assess how sepsis program investments impact outcomes
- Fluids are frequently needed for sepsis patients, but recognize that they can have side effects
- Use dynamic clinical judgment, with ongoing patient reassessment



Sepsis: where are we today?





Sepsis: where are we going tomorrow? Frontiers of sepsis care





Thank you







Email: vincent.x.liu@kp.org john.w.morehouse@kp.org carmen.l.adams@kp.org

Funders: NIH/NIGMS K23GM112018 (VL) Gordon & Betty Moore Foundation The Permanente Medical Group Kaiser Foundation Health Plan

